Scandion Oncology enhances its external communication

Scandion Oncology, the Cancer Drug Resistance Company, today announced that Mads Kronborg, bringing more than a decade of corporate communication and investor relations experience in the global life-science industry, will now help plan and drive its external communication.

Scandion Oncology, a biotech company developing first-in-class medicines aimed at treating cancer which has developed resistance against current treatment options, now strengthens its external communication capabilities.

 

Effective today, Mads Kronborg, former Head of Corporate Communication and Media Relations at pharmaceutical company Lundbeck and former Head of Investor Relations & Communication at biotech company Zealand Pharma, joins Scandion Oncology acting as Head of External Communication. In total, Mads Kronborg has more than a decade of corporate communication and investor relations experience in the global life-science industry.

 

In his role at Scandion Oncology, Mads Kronborg will help plan and drive the company’s communication with media, investors and analysts. The collaboration follows Scandion Oncology’s intent to further enhance its external communication.

 

“As we continue to build and develop Scandion Oncology and our pipeline of potential new first in class medicines we highly prioritize communication with our external stakeholders. We are happy to have Mads Kronborg help lead these efforts and are looking forward to benefit from his many years of experience in the industry”, says Bo Rode Hansen, President & CEO of Scandion Oncology.

 

A journalist by education, Mads Kronborg spent 12 years with Lundbeck. From 2009 he served as the company’s Head of Corporate Media Relations before being appointed Head of Corporate Communication in 2015. In 2020, he joined Zealand Pharma and today works as an independent advisor within strategic communication and reputation management.

 

“I am excited to work with Scandion Oncology and help communicate the company’s development and promising pipeline to its external audience. Scandion Oncology has the potential to significantly improve cancer treatment and I am thrilled to support the company as it works towards fulfilling that potential”, says Mads Kronborg.

 

For further information please contact:

Mads Kronborg, Head of External Communication

Phone: +45 6051 4955

E-mail: ir@scandiononcology.com

 

The information was provided by the contact person above for publication on January 12, 2022, at 09.00 CET.

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.

 

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.